Virtual Library

Start Your Search

G. Krakorova



Author of

  • +

    P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P3.01-021 - New Perspectives for the Patients with ALK Positive Lung Adenocarcinomas, after Failure of Crizotinib Therapy. A Single Institution Experience (ID 2801)

      09:30 - 09:30  |  Author(s): G. Krakorova

      • Abstract
      • Slides

      Background:
      Patients suffering from ALK-rearranged non-small cell lung cancer (NSCLC) should have significant benefit of ALK inhibitor targeted therapy by crizotinib. Even if high frequency of response rate to this therapy is documented, wast majority of those tumors become resistent due to overgrow of secondary resistent mutations bearing tumour cells. Such resistence should be overcome with the help of an alternative second generation ALK inhibitors.

      Methods:
      We present our diagnostic and therapeutic single institution experience in patients having ALK-rearranged NSCLC, as examined by FISH. We also present two case reports of patients treated by a second generation ALK inhibitor (ceritinib) after failure of the initial crizotinib therapy.

      Results:
      Between January 2011 and January 2015, a total of 595 tumour tissue samples were prospectively analysed for a presence of ALK rearrangements. A conclusive FISH result was obtained from a subset of 483. ALK rearranement was found in 15 patients (3.1%). The group consisted of 9 males and 6 females, with a median age of 65. 13 of the tumours were adenocarcinomas, 2 adenosquamous carcinomas. 8 patients were nonsmokers, seven were smokers. Consequently, 6 patients were treated by crizotinib while the rest did show a rapidly progressing tumours. 3 of the 6 crisotinib patients had a documented benefit from the therapy lasting for 22, 15 and 6 months.Finally, after failure of crizotinib, 2 patients reached a second partial remission on ceritinib,lasting 9 and 6 months.

      Conclusion:
      Targeted therapy of ALK-positive tumours is capable to prolong survival of patients quite significantly. In crizotinib - resistent tumours, second generation ALK inhibitors (such as ceritinib in this case), maybring further benefits to patients.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.